Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA® in Patients With Hypoparathyroidism

NCT03516773 is registered in ClinicalTrials.gov with Entera Bio Ltd. as lead sponsor.

NCT NCT03516773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03516773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA® in Patients With Hypoparathyroidism
Lead sponsor
Entera Bio Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 17, 2018
Completion date
February 24, 2019
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypoparathyroidism